Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: A 4-year study
Por:
Valdés-González R.A., Dorantes L.M., Garibay G.N., Bracho-Blanchet E., Mendez A.J., Dávila-Pérez R., Elliott R.B., Terán L., White D.J.G.
Publicada:
1 ene 2005
Resumen:
Objective: Porcine islets of Langerhans for xenotransplantation into humans have been proposed as a solution to the shortage of human donors. Rejection is one of the main constraints. This study presents the results of a clinical trial using a novel method for transplanting and immunoprotecting porcine islets in type 1 diabetic patients. Design: A 4-year follow up of a clinical trial involving 12 patients, with no immunosuppressive drugs at any point. Eleven age matched untransplanted diabetics served as controls. Methods: We have developed a procedure for protecting neonatal porcine islets by combining them with Sertoli cells and placing them in a novel subcutaneous autologous collagen-covered device. Results: In the patients in the treatment group, no complications arose and no porcine endogenous retrovirus infection was detected. Half of the patients showed a significant reduction in insulin requirements compared with both their pre transplant levels and controls, and this reduction was maintained for up to 4 years. Two patients became insulin-independent for several months. Porcine insulin was detected in three patients' sera following glucose stimulation up to 4 years post transplant. Three years post transplant, one of four devices was removed from four patients, and the presence of insulin-positive cells in the transplant was demonstrated by immunohistology in all 4 patients. Conclusions: Long-term cell survival with concurrent positive effects on metabolic control are possible by this technique. © 2005 Society of the European Journal of Endocrinology.
Filiaciones:
Valdés-González R.A.:
Facultad de Medicina, Universidad Nacional Autónoma de México, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Xenotransplant Laboratory, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Dorantes L.M.:
Department of Endocrinology, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Garibay G.N.:
Department of Endocrinology, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Bracho-Blanchet E.:
Department of Surgery, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Mendez A.J.:
Diabetes Research Institute, University of Miami, Miami, FL, United States
Dávila-Pérez R.:
Department of Surgery, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
Elliott R.B.:
Diatranz Ltd., Auckland, New Zealand
Terán L.:
Xenotransplant Laboratory, Hospital Infantil de México 'Federico Gómez', Calle Dr. Márquez 162, 06720 México, D.F., Mexico
White D.J.G.:
Robarts Research Institute, University of Western Ontario, London, Ont., Canada
All Open Access, Bronze
|